Controlled Drug Delivery of Hydrophobic Drug
Development and Evaluation of Oral Controlled Drug Delivery of BCS Class-II Drug Glipizide
Versandkostenfrei!
Versandfertig in 6-10 Tagen
36,99 €
inkl. MwSt.
PAYBACK Punkte
18 °P sammeln!
Glipizide, an oral hypoglycemic agent, is one of the most commonly prescribed drugs for the treatment of patients with type II diabetes mellitus. It is practically water-insoluble, thus it belongs to class-II of Biopharmaceutical Classification System (BCS). Glipizide has a relatively short elimination half-life (2-4 h), thereby requiring twice daily dosing in large number of patients, which often leads to non-compliance. Thus, there is a strong clinical need and market potential for a dosage form that will deliver glipizide in a controlled manner to a patient needing this therapy, thereby res...
Glipizide, an oral hypoglycemic agent, is one of the most commonly prescribed drugs for the treatment of patients with type II diabetes mellitus. It is practically water-insoluble, thus it belongs to class-II of Biopharmaceutical Classification System (BCS). Glipizide has a relatively short elimination half-life (2-4 h), thereby requiring twice daily dosing in large number of patients, which often leads to non-compliance. Thus, there is a strong clinical need and market potential for a dosage form that will deliver glipizide in a controlled manner to a patient needing this therapy, thereby resulting in a better patient compliance. The aim of present investigation was to enhance the solubility by using beta-cyclodextrin binary complexation and impart a controlled release in a single formulation in order to reduce dosing frequency.
Andere Kunden interessierten sich für
